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Early mortality on antiretroviral therapy (ART) in low-income 
countries is substantially higher than in high-income countries.1 
Mortality during the first year on ART in sub-Saharan Africa has 
ranged from 8% to 26%.2 Main causes of early death in cohort 
studies from sub-Saharan Africa include tuberculosis, acute sepsis, 
cryptococcal meningitis, malignancies and chronic diarrhoea or 
wasting syndromes.2 Less is known about causes of death later in 
the course of ART. In high-income countries, there is increasing 
emphasis on non-HIV infection-related causes of death.3 This study 
describes the causes of death in a large single-centre cohort on ART 
according to time on treatment and, in particular, death beyond the 
first year on ART.
Methods
Chris Hani Baragwanath Hospital is a 2 700-bed university-associated 
public sector hospital serving Soweto. WHO stage 4 diseases (AIDS) 
or a CD4 cell count ≤200 cells/μl qualify patients for ART, usually 
comprising stavudine, lamivudine and efavirenz. Cotrimoxazole 
prophylaxis was provided too. Frequent clinic visits were scheduled 
for the first 6 months, after which clinically well patients were seen 
less frequently.
A retrospective cohort study was conducted of the 2 943 adult 
patients (≥18 years of age) who initiated ART between 1 April 2004 
and 31 December 2005. Patients were followed till January 2009 for 
a median of 2.7 years.
Causes of death were assigned by attending doctors in the 
hospital wards and HIV clinic. For patients who died at home, an 
attempt was made to differentiate sudden unexpected death from 
chronic ill-health. Family members of patients who died at home 
were informally asked the symptoms and cause of death as part 
of routine follow-up of patients who missed appointments or if 
family members reported the death. The researcher reviewed clinic 
records, inpatient hospital files and laboratory investigations on all 
patients who died, and designated a final cause of death. Acute sepsis 
included acute pneumonia, acute bacterial meningitis, septicaemia 
and other severe bacterial infections. Chronic medical conditions 
included diabetes mellitus, chronic cardio-respiratory diseases and 
renal diseases (excluding HIV-associated nephropathy). Unmasking 
of an appropriate opportunistic disease within 6 months of starting 
effective ART was adjudged to be immune reconstitution disease 
(IRD). Patients were considered lost to follow-up if not seen in the 6 
months preceding the close of the study.
The study was approved by the Committee for Research on Human 
Subjects of the University of the Witwatersrand.
Chi-squared test calculations or Fisher’s exact test were used for 
group comparisons.
Results
Death was known to have occurred in 305 (10.4%) of the 2 943 
patients. The median age of those who died was 36 years (range 19 
- 69 years) and the median CD4 count at baseline was 26/μl (range 1 - 
479/μl). Table 1 compares baseline characteristics of 305 patients who 
died with the 2 638 survivors. Comparing the baseline characteristics 
of the 268 patients who died ≤12 months on ART with the 37 who 
died >12 months on ART, significantly more died in the first 12 
months with CD4 <50 cells/μl (193 (72%) v. 18 (49%) (p=0.0039)) 
and with WHO stage 4 disease (168 (63%) v. 12 (32%) (p=0.0004)).
Of those who died, 165 (54%) died in the first 3 months on ART, 
53 (17%) in months 4 - 6, 50 (16%) in months 7 - 12, 22 (7%) in the 
second year, 9 (3%) in the third year, and 6 (2%) beyond 3 years. Over 
the study period, 268 (9.1%) patients were lost to follow-up.
A specific cause of death was retrospectively assigned to 275 (90%) 
patients. There was no information on 22 (7%) of the deaths, and 8 
(3%) had a sudden unexpected death at home. More than one cause 
was found in 14 patients.
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This retrospective cohort study describes causes of death in 305 
patients (baseline median CD4 count 26/μl) from 2 943 adults on 
antiretroviral therapy. Acute sepsis (20%), tuberculosis (18%) and 
Mycobacterium avium complex (MAC) bacteraemia (14%) were 
the most common causes. Mortality owing to the disease was 66% 
for MAC bacteraemia and 23% for non-Hodgkin’s lymphoma. In 
37 patients dying beyond one year on ART, virological failure was 
present in 11 (30%), and non-HIV-related causes of death occurred 
in 10. The main causes were acute sepsis (6), tuberculosis (7) and 
chronic medical conditions (5). Initiating ART at higher CD4 
counts should reduce early mortality.
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Table 1. Baseline characteristics of patients who survived and 
those who died
Surviving cohort
N (%)
Deaths
n (%) p-value
Total number 2 638 305
Male 1 030 (39%) 118 (39%) NS
CD4 <50/μl 936 (35%) 211 (69%) <0.0001
HIV-1 RNA 
≥100 000 copies/ml 1 556 (59%) 221 (72%) <0.0001
WHO stage 3 1 123 (43%) 84 (28%) <0.0001
WHO stage 4 615 (23%) 180 (60%) <0.0001
NS = Not significant.
RESEARCH
681  August 2012, Vol. 102, No. 8  SAMJ
Acute sepsis (20%), TB (18%) and Mycobacterium avium complex 
(MAC) bacteraemia (14%) were the most common causes of death 
(Fig. 1). Of 64 with confirmed MAC bacteraemia in the total cohort, 
42 (66%) died from the condition. Standard initial treatment of 
MAC bacteraemia included clarithromycin with ethambutol and 
a third drug, usually ciprofloxacin. Lactic acidosis as a toxicity 
owing predominantly to stavudine was implicated in 11 (3.6%) 
deaths. The 21 AIDS-defining cancers causing death comprised 
Kaposi’s sarcoma (12), non-Hodgkin’s lymphoma (6), Burkitt’s 
lymphoma (1), and carcinoma of the cervix (2). Of 30 in the cohort 
with non-Hodgkin’s lymphoma, 7 (23%) died. The 7 non-AIDS 
defining malignancies were 3 with Hodgkin’s lymphoma, and 1 each 
with carcinoma of the lung, anus and oesophagus, and one with 
acute myeloid leukaemia. Chronic medical conditions included 
9 patients with cardiac disease (4 with dilated cardiomyopathy, 
2 with rheumatic heart disease, and 1 each with atrial myxoma, 
third-degree heart block, and aortic aneurysm), 5 with chronic 
lung disease, 3 with chronic renal failure predating ART, and 3 
with diabetes mellitus. Sepsis was microbiologically defined in 
15 (25%) patients with acute sepsis including 3 patients with 
bacterial meningitis (2 with Streptococcus pneumoniae and 1 with 
non-typhoidal salmonella who was also bacteraemic) and 13 with 
bacteraemia (5 with Escherichia coli, 4 with Staphylococcus aureus 
and 4 with non-typhoidal salmonella). Unmasking IRD comprised 
4 patients with tuberculosis and 2 with MAC infection.
Deaths in hospital occurred in 39 (78%) of 50 patients who 
died after 7 - 12 months on ART and in 26 (70%) of 37 who died 
after >12 months on ART. Virological failure (viral load >400 
copies/ml) was noted in 9 (18%) who died in months 7 - 12, and 
11 (30%) who died beyond the first year; 8 of the latter 11 died 
of sepsis, tuberculosis or MAC bacteraemia. Common causes of 
death >12 months after starting ART were acute sepsis (16%), TB 
(19%; 5 cultured; 1 each with multi-drug resistance and rifampicin 
monoresistance), and chronic medical conditions (14%). Non-
HIV-related causes were found in 10 patients, comprising chronic 
medical conditions (5), motor vehicle accident (2), and 1 each 
with cancer of the anus, pulmonary embolism (in a patient 
with chronic diarrhoea related to intestinal spirochaetosis), and 
postoperative complications. Three patients died of lactic acidosis 
in the second year.
Discussion
The most striking finding of this study among AIDS-related causes 
of death, in contrast with other African studies,2,4 was the importance 
of MAC bacteraemia. It has been recognised as an important 
opportunistic infection in countries in sub-Saharan Africa in studies 
employing mycobacterial blood cultures.5-6 It is associated with a 
high mortality in the ART era with only 30% of such patients alive 
beyond 2 years.7 Treatment failure is common, reasons including 
drug toxicity, inadequate serum levels and development of drug 
resistance. Primary prophylaxis with clarithromycin or azithromycin 
for patients with CD4 cell counts <50 - 100/μl might have prevented 
cases prior to ART.
TB and cryptococcal meningitis have been the leading causes of 
death in most other African studies.2,4 Cryptococcal meningitis was 
a less common cause in this study.2,4 Bacterial causes of death, other 
than mycobacterial infections, have not been well-defined in ART 
studies. The organisms found are common in patients with HIV 
infection.2
Among non-Hodgkin’s lymphoma patients co-infected with 
HIV in California, 59% died within 2 years of diagnosis compared 
with 30% without HIV infection.8 In Uganda, only 20 of 154 
patients with non-Hodgkin lymphoma, irrespective of HIV status, 
were known to be alive a year after diagnosis.9 The outcome in this 
study appears better but merits a dedicated study as some patients 
who died might not have accessed ART. Non-AIDS-defining 
cancers are likely to increase with longer duration on ART and 
increasing age.
Unmasking IRD was an uncommon cause of death, as it was in 
Uganda.4 Two missing causes of death, compared with other settings,3 
were liver failure, possibly owing to low rates of hepatitis C infection 
in this cohort and the activity of lamivudine against hepatitis B, and 
ischaemic heart disease, since coronary atherosclerosis is uncommon 
in this population.10
This study mirrored the high first-year mortality in cohorts in 
sub-Saharan Africa.2,4 Mortality was low beyond 1 year on ART, as in 
similar studies.2,4 Beyond 12 months of ART, virological failure was a 
prominent finding in those who died. This was partially responsible 
for the continued importance of TB, MAC bacteraemia and acute 
sepsis, accounting for half of these cases. Non-HIV-related causes, 
especially chronic medical conditions, acquired increased relative 
prominence.
This study has some 
potential limitations. Many 
patients were lost to follow-
up, some of whom probably 
died.11 Missed deaths might 
have affected the ranking of 
causes of death. No autopsies 
were performed. There was no 
formal verbal autopsy for those 
who died at home, and not all 
of those had a family member 
interviewed.
The study strength, despite 
its retrospective nature, was 
that ascertainment of cause of 
death was as accurate as could 
be achieved without autopsies. 
Those who died having received 
ART for <6 months were seen 
frequently as in- or outpatients. 
Of the patients who died having Fig. 1. Causes of death of 268 patients on ART ≤12 months and 37 patients on ART >12 months.
TB Tuberculosis; MAC Mycobacterium avium complex bacteraemia; ADC AIDS-dening cancer; CCM Cryptococcal meningitis; PTED Pulmonary thromboembolic disease; 
LA Lactic acidosis; NADC Non-AIDS-dening cancer; CMV Cytomegalovirus infection; MVA Motor vehicle accident.
P=0.0132 for chronic medical condition for ≤12 months vs. >12 months. Others all non- signicant.
Causes of death not included in gure include unexplained wasting (5 patients), cerebral infarction (4) , and 1 patient each with toxoplasmosis, HIV cholangiopathy, 
thrombotic thrombocytopaenic purpura, suicide, aplastic anaemia, subdural haematoma, and over-warfarinisation.
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been on ART >6 months, 75% died in hospital. Both groups could 
be investigated at a tertiary level. Studies such as this involving 
the clinical record are important as death certificates and routine 
surveillance data are less accurate.12 There is also an inherent tension 
between clinical assignment and public health coding of cause of 
death for the purposes of public health planning, programmes and 
evaluation. Some clinical causes have been labelled ‘garbage coding’, 
including categories such as sepsis and pulmonary embolism since 
each has an underlying cause to precipitate the chain of events leading 
to death.13 In this study, that underlying cause was AIDS.
In conclusion, MAC bacteraemia was an important cause of 
death not highlighted in other African studies. Access to treatment 
of malignancy may improve outcomes. Virological failure and non-
HIV-related causes were prominent beyond the first year on ART. 
Initiating ART at higher CD4 counts should reduce early mortality 
and increase the relative importance of non-HIV-related causes of 
death over time.14
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BATELEUR
There are no wings  
that hold the high, 
invisible strings of the sky 
with the same, silent elegance 
as this puppeteer … 
no act, no acrobat
to steer without force 
its course through the elements: 
to pull right, 
to lean left 
to balance on air … 
like a bateleur.
There is no sight  
no heaven’s flight 
that calls to my soul 
with the same delight 
as this calligrapher …
no scribe, no sculptor   
to better define    
the god-like lines  
of an  avatar: 
to be less afraid of heights, 
to be less afraid to fall …
From ‘Untamed’ 
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